Table 2 Baseline ocular surface indicators and biomarkers (with significant differences) in the intended HSCT cohort vs. controls.

From: Ocular surface indicators and biomarkers in chronic ocular graft-versus-host disease: a prospective cohort study

 

Intended HSCT Cohort

Controls

 
 

Na

Median (Range)

Na

Median (Range)

Wilcoxon p value

Ocular Surface Indicators

 OSDI

40

2.1 (0.0, 37.5)

12

4.2 (0.0, 12.5)

0.51

 Oxford Corneal Staining Score

76

1.7 (0.0, 8.7)

40

0.0 (0.0, 1.8)

<0.0001

 Schirmer’s Test (mm)

78

10.0 (3.0, 35.0)

38

11.0 (2.0, 35)

0.41

 Tear Osmolarity (mOsm/L)

76

305 (284, 378)

40

301 (281, 352)

0.06

 TBUT (seconds)

74

8.0 (2.3, 13.0)

38

8.0 (3.3, 12.0)

0.80

Significant Tear Biomarkers (pg/mL)b

 RANTES

69

70.4 (0.0, 343.0)

39

190.2 (9.8, 628.0)

<0.0001

 TNF-α

69

20.0 (1.3, 109.0)

39

11.2 (0.0, 30.5)

<0.0001

Significant Serum Biomarkers (pg/mL)b

 IL-8

34

10.2 (3.3, 957)

18

4.5 (0.0, 38.9)

0.0008

 TNF-α

34

8.7 (0.0, 18.1)

18

4.2 (1.5, 9.2)

<0.00001

 Dry Eye Disease (%)c

(15) 37.5%

(5) 25.0%

0.27

  1. aN corresponds to the number of participants for OSDI, serum biomarkers, and Dry Eye Disease; otherwise, corresponds to number of eyes.
  2. bNon-significant biomarkers are presented in Supplementary Table 1.
  3. cDry Eye Disease was defined according to 2007 TFOS DEWS Report. Of note, this definition was updated in the 2017 TFOS DEWS II Report Executive Summary, which was published after data collection was completed.
  4. HSCT hematopoietic stem cell transplant, OSDI ocular surface disease index, TBUT tear break-up time.
Back to article page